Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia

被引：5
作者：
Khazal, Sajad [1 ]
Kebriaei, Partow [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Pediat Pediat Stem Cell Transplantat & Cellul, Childrens Canc Hosp, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 11期
关键词：
Blinatumomab; CAR-T cell; Hematopoietic cell transplantation; Immunotherapy; Inotuzumab; CAR-T-CELLS; MINIMAL RESIDUAL DISEASE; B-CELL; INOTUZUMAB OZOGAMICIN; SINGLE-ARM; ADULT PATIENTS; BLINATUMOMAB; REMISSION; SAFETY; CHEMOTHERAPY;
D O I：
10.1016/j.clml.2020.06.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite high complete remission (CR) rates, relapse remains a significant problem among subsets of patients with B acute lymphoblastic leukemia (ALL), and is associated with poor prognosis. The recent Food and Drug Administration approval of highly effective immunotherapies for B-lineage ALL (B-ALL), blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, a chimeric antigen receptor (CAR) modified T-cell therapy, targeting CD19, or CD22, have dramatically changed the therapeutic landscape for the treatment of B-ALL, resulting in high rates of deep and durable remissions. Therefore, there is now debate regarding the role of allogeneic hematopoietic cell transplantation (HCT) in this new landscape. Herein, we review these novel agents, and discuss the sequence of therapy, including allogeneic HCT in B-ALL.
引用
收藏
页码：713 / 719
页数：7
相关论文
共 47 条
  • [1] [Anonymous], 2016, J CLIN ONCOL
  • [2] [Anonymous], 2015, BLOOD
  • [3] [Anonymous], 2018, BLOOD S1, DOI DOI 10.1182/BLOOD-2018-99-111531
  • [4] Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Benjamin, Reuben
    Graham, Charlotte
    Yallop, Deborah
    Jozwik, Agnieszka
    Ciocarlie, Oana
    Jain, Nitin
    Jabbour, Elias J.
    Maus, Marcela V.
    Frigault, Matthiew
    Boissel, Nicolas
    Larghero, Jerome
    Baruchel, Andre
    Mohty, Mohamad
    De Moerloose, Barbara
    Bloor, Adrian
    Frey, Noelle V.
    Zinai, Amina
    Balandraud, Svetlana
    Philippe, Anne
    Fouliard, Sylvain
    Gauthier, Ludiane
    Pauly, Jeanne
    Konto, Cyril
    Bermingham, Candy
    Veys, Paul
    Qasim, Waseem
    [J]. BLOOD, 2018, 132
  • [5] Bhojwani D, 2019, LEUKEMIA, V33, P884, DOI 10.1038/s41375-018-0265-z
  • [6] Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
    Brudno, Jennifer N.
    Somerville, Robert P. T.
    Shi, Victoria
    Rose, Jeremy J.
    Halverson, David C.
    Fowler, Daniel H.
    Gea-Banacloche, Juan C.
    Pavletic, Steven Z.
    Hickstein, Dennis D.
    Lu, Tangying L.
    Feldman, Steven A.
    Iwamoto, Alexander T.
    Kurlander, Roger
    Maric, Irina
    Goy, Andre
    Hansen, Brenna G.
    Wilder, Jennifer S.
    Blacklock-Schuver, Bazetta
    Hakim, Frances T.
    Rosenberg, Steven A.
    Gress, Ronald E.
    Kochenderfer, James N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1112 - +
  • [7] Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
    Davila, Marco L.
    Riviere, Isabelle
    Wang, Xiuyan
    Bartido, Shirley
    Park, Jae
    Curran, Kevin
    Chung, Stephen S.
    Stefanski, Jolanta
    Borquez-Ojeda, Oriana
    Olszewska, Malgorzata
    Qu, Jinrong
    Wasielewska, Teresa
    He, Qing
    Fink, Mitsu
    Shinglot, Himaly
    Youssif, Maher
    Satter, Mark
    Wang, Yongzeng
    Hosey, James
    Quintanilla, Hilda
    Halton, Elizabeth
    Bernal, Yvette
    Bouhassira, Diana C. G.
    Arcila, Maria E.
    Gonen, Mithat
    Roboz, Gail J.
    Maslak, Peter
    Douer, Dan
    Frattini, Mark G.
    Giralt, Sergio
    Sadelain, Michel
    Brentjens, Renier
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
  • [8] CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
    Fry, Terry J.
    Shah, Nirali N.
    Orentas, Rimas J.
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Ramakrishna, Sneha
    Wolters, Pamela
    Martin, Staci
    Delbrook, Cindy
    Yates, Bonnie
    Shalabi, Haneen
    Fountaine, Thomas J.
    Shern, Jack F.
    Majzner, Robbie G.
    Stroncek, David F.
    Sabatino, Marianna
    Feng, Yang
    Dimitrov, Dimiter S.
    Zhang, Ling
    Sang Nguyen
    Qin, Haiying
    Dropulic, Boro
    Lee, Daniel W.
    Mackall, Crystal L.
    [J]. NATURE MEDICINE, 2018, 24 (01) : 20 - +
  • [9] Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
    Gardner, Rebecca A.
    Finney, Olivia
    Annesley, Colleen
    Brakke, Hannah
    Summers, Corinne
    Leger, Kasey
    Bleakley, Marie
    Brown, Christopher
    Mgebroff, Stephanie
    Kelly-Spratt, Karen S.
    Hoglund, Virginia
    Lindgren, Catherine
    Oron, Assaf P.
    Li, Daniel
    Riddell, Stanley R.
    Park, Julie R.
    Jensen, Michael C.
    [J]. BLOOD, 2017, 129 (25) : 3322 - 3331
  • [10] Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Dombret, Herve
    Bonifacio, Massimiliano
    Reichle, Albrecht
    Graux, Carlos
    Faul, Christoph
    Diedrich, Helmut
    Topp, Max S.
    Brueggemann, Monika
    Horst, Heinz-August
    Havelange, Violaine
    Stieglmaier, Julia
    Wessels, Hendrik
    Haddad, Vincent
    Benjamin, Jonathan E.
    Zugmaier, Gerhard
    Nagorsen, Dirk
    Bargou, Ralf C.
    [J]. BLOOD, 2018, 131 (14) : 1522 - 1531
12345